<SEC-DOCUMENT>0001193125-25-050395.txt : 20250310
<SEC-HEADER>0001193125-25-050395.hdr.sgml : 20250310
<ACCEPTANCE-DATETIME>20250310073342
ACCESSION NUMBER:		0001193125-25-050395
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20250310
DATE AS OF CHANGE:		20250310

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PLUS THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001095981
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				330827593
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-280061
		FILM NUMBER:		25722157

	BUSINESS ADDRESS:	
		STREET 1:		4200 MARATHON BLVD.
		STREET 2:		SUITE 200
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78756
		BUSINESS PHONE:		737.255.7194

	MAIL ADDRESS:	
		STREET 1:		4200 MARATHON BLVD.
		STREET 2:		SUITE 200
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78756

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTORI THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20050712

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MACROPORE INC
		DATE OF NAME CHANGE:	20010320
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d940738d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-280061</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT NO. 8 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(To Prospectus dated
June&nbsp;24, 2024) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g940738g0310061942310.jpg" ALT="LOGO" STYLE="width:1.69097in;height:0.975694in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Plus Therapeutics Inc. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement updates and supplements the prospectus, dated June&nbsp;24, 2024 (as supplemented to date, the &#147;Prospectus&#148;), which forms
a part of our registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (<A HREF="http://www.sec.gov/Archives/edgar/data/1095981/000119312524167044/d840996d424b3.htm">No. <FONT STYLE="white-space:nowrap">333-280061</FONT></A>). This
prospectus supplement is being filed to update and supplement the information in the Prospectus with the information contained in our Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the Securities and Exchange
Commission on March&nbsp;10, 2025 (the &#147;Current Report&#148;). Accordingly, we have attached the Form <FONT STYLE="white-space:nowrap">8-K</FONT> to this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement should be read in conjunction with the Prospectus, which is to be delivered with this prospectus supplement, and is qualified by
reference thereto, except to the extent that the information in this prospectus supplement updates or supersedes the information contained in the Prospectus. Please keep this prospectus supplement with your Prospectus for future reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock, par value $0.001 per share (&#147;Common Stock&#148;) is listed on The Nasdaq Capital Market LLC under the symbols &#147;PSTV&#148;. On
March&nbsp;7, 2025, the closing price of our Common Stock was $1.57. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a &#147;smaller reporting company&#148; for purposes of federal securities
laws and are subject to reduced public company reporting requirements. Accordingly, the information in the Prospectus and this prospectus supplement may not be comparable to information provided by companies that are not smaller reporting companies.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Our business and investment in our Common Stock involve significant risks. These risks are described in the section titled &#147;Risk Factors&#148;
beginning on page 13 of the Prospectus, and under similar headings in any amendments or supplements to the Prospectus. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and
Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal
offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is March&nbsp;10, 2025. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): March 7, 2025 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g938890g0310055711355.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:1pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>PLUS THERAPUETICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-34375</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">33-0827593</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>4200 Marathon Blvd., Suite 200 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Austin, Texas 78756 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (737) <FONT STYLE="white-space:nowrap">255-7194</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&nbsp;12(b) of the Act: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of each class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Trading<BR>Symbol</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of each exchange<BR>on which registered</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Common Stock, $0.001 par value per share</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">PSTV</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">The Nasdaq Capital Market</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744;&#8194;Emerging Growth Company </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&#8194;&#9744;
</P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%" VALIGN="top" ALIGN="left"><B>Item&#8201;8.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other Events. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Plus Therapeutics, Inc. (the &#147;Company&#148;) has announced that the Nasdaq Stock Market LLC (&#147;Nasdaq&#148;) has confirmed in a letter dated
March&nbsp;7, 2025 (the &#147;Letter&#148;) that the Company has regained compliance with Nasdaq&#146;s minimum stockholders&#146; equity requirement under Nasdaq Listing Rule 5550(b)(1) (the &#147;Minimum Stockholders&#146; Equity
Requirement&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As previously disclosed by the Company in a <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001095981/000119312524249270/d860547d8k.htm">Current
 Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT></A> filed on November&nbsp;1, 2024, Nasdaq had provided the Company until March&nbsp;4, 2025, to notify Nasdaq that the Company was in compliance with the Minimum Stockholders&#146; Equity
Requirement. The Company regained compliance with the Minimum Stockholders&#146; Equity Requirement in connection with the private placement (the &#147;Private Placement&#148;) disclosed by the Company in its <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001095981/000119312525045305/d875007d8k.htm">Current
 Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT></A> filed on March&nbsp;4, 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the receipt of the Letter, the funds from the
Company&#146;s previously disclosed Private Placement are being released from escrow. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to Nasdaq Listing Rule 5815(d)(4)(B), the Company will be
subject to a Mandatory Panel Monitor until March&nbsp;7, 2026. If the Nasdaq Listing Qualifications staff (the &#147;Staff&#148;) finds the Company again out of compliance with the Minimum Stockholders&#146; Equity Requirement before that date, the
Company would not be permitted to provide the Staff with a plan of compliance with respect to that deficiency and the Staff would not be permitted to grant additional time for the Company to regain compliance with respect to that deficiency, nor
would the Company be afforded an applicable cure or compliance period. Instead, the Staff would issue a &#147;Delist Determination Letter&#148; and the Company would have an opportunity to request a Nasdaq hearing panel regarding its continued
listing. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>PLUS THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date: March&nbsp;10, 2025</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Andrew Sims</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Andrew Sims</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g938890g0310055711355.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g938890g0310055711355.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !> *4# 2(  A$! Q$!_\0
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MKJ'B[0-+OVL;W48HKI0"T95B1GIT%88BA[9)7M8Z<+B?8-NU[GG7_"P/$O\
M?B_\!Z/^%@>)<??B_P# >O2]4\2Z+HGD_P!HWT=OYZ[H]RD[AZ\"K=IJ-E?V
M"WUI<136K+N$J'*XK'ZM5_Y^,W^N4?\ GTOZ^15T:>35?#MM->@,]Q%^\&W
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$% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g940738g0310061942310.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g940738g0310061942310.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !< * # 2(  A$! Q$!_\0
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MHH **3-&: %HHHH **** "BDS10 M%%)F@!:*3-&: %HI,TM !1110 4444
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-* %HI** %HI** /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
